P/B
141,4
Axsome Therapeutics
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
$11.8B
Market Cap • 9/11/2026
2012
(14 years)
Founded
2015
(11 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
15,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,6
EPS
—
Market Cap
Market Cap
11,8B
EV
11,7B
EV/Revenue
15
EV/EBITDA
-66,3
EV/EBIT
-62,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,9%
Total Yield
-0,9%
Payout
0%
Retained Earnings
-1,4B
Profitability
Gross Margin
93,2%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
24,2%
Capex/Revenue
0,1%
Capex/D&A
7%
Capex/OCF
-1%
SBC/OCF
—
% PPE
2,6%
% Goodwill
1,6%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
11,6%
CAGR Net Income 5Y
11%
CAGR EPS 5Y
4,4%
CAGR OCF 5Y
-4,3%
Leverage
N.D./EBITDA
0,6
Debt/Equity
0%
Current Ratio
1,4
Quick Ratio
1,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!